Bosutinib is an investigational orally available dual Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and PDGFR.1

The Philadelphia Chromosome, a hallmark abnormal chromosome of chronic myeloid leukemia (CML), initiates a series of events leading to the development of Bcr-Abl, a tyrosine kinase that causes CML cells to reproduce rapidly.2 In some cases, CML develops resistance to therapies that focus strictly on the inhibition of the Bcr-Abl tyrosine kinase.3 Newer therapies target the inhibition of both Src and Abl tyrosine kinases to help overcome this resistance,4 as overexpression of the Src family of tyrosine kinases have been implicated in imatinib resistance and CML progression.2

It is believed that by dual inhibition of the Src and Abl tyrosine kinases, bosutinib may inhibit signaling in CML cells that allows the cells to grow, survive and reproduce.2

**The following studies are ongoing but closed to enrollment:**

**Chronic Myeloid Leukemia:**

**Phase 3**
- **BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) Study:** Randomized, open-label study of bosutinib versus imatinib in subjects with newly diagnosed chronic phase Philadelphia chromosome positive CML5

**Phase 1/2**
- **Study 200:** Bosutinib monotherapy in CML in patients resistant or intolerant to imatinib +/- other tyrosine kinase inhibitors6

For more information, please visit www.pfizercancertrials.com or www.clinicaltrials.gov or call toll-free 1-877-369-9753 (in the United States and Canada) or +1-646-277-4066 (outside of the United States and Canada).


